SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $600 | -53.8% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $1,300 | -26.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,760 | -43.9% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $3,140 | -37.2% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $5,000 | +25.0% | 1,000 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $4,000 | -33.3% | 1,000 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $6,000 | -25.0% | 1,000 | 0.0% | 0.00% | -20.0% |
| Q4 2021 | $8,000 | -11.1% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q3 2021 | $9,000 | -25.0% | 1,000 | 0.0% | 0.01% | -22.2% |
| Q2 2021 | $12,000 | -7.7% | 1,000 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $13,000 | -18.8% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q4 2020 | $16,000 | +77.8% | 1,000 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $9,000 | 0.0% | 1,000 | 0.0% | 0.01% | -20.0% |
| Q2 2020 | $9,000 | +28.6% | 1,000 | -12.5% | 0.01% | +25.0% |
| Q1 2020 | $7,000 | -12.5% | 1,143 | +14.3% | 0.01% | -11.1% |
| Q4 2019 | $8,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 968,505 | $12,135,000 | 1.23% |
| Golden State Equity Partners | 126,608 | $1,586,000 | 0.90% |
| McGuire Investment Group, LLC | 272,801 | $3,418,000 | 0.72% |
| Lombard Odier Asset Management (Switzerland) SA | 848,429 | $10,631,000 | 0.70% |
| Rhenman & Partners Asset Management AB | 765,000 | $9,585,000 | 0.67% |
| EMC Capital Management | 72,061 | $903,000 | 0.64% |
| WASATCH ADVISORS LP | 10,328,423 | $129,415,000 | 0.58% |
| Ceeto Capital Group, LLC | 74,000 | $927,000 | 0.45% |
| Fort Sheridan Advisors LLC | 75,945 | $952,000 | 0.38% |
| Vanguard Capital Wealth Advisors | 34,580 | $388,679,000 | 0.33% |